Spotlight On... Sanofi commits to developing Zika vax while other big players will evaluate; Perrigo expands recall of children's cold med; AmerisourceBergen reports for Q4 2015; Porton adds to U.K. manufacturing; and more...

Sanofi ($SNY) says it intends to apply its decades of vaccine development work and manufacturing expertise in dengue fever to try to create a vaccine for Zika virus, the mosquito-borne disease that the World Health Organization this week called a global health emergency. The other large vaccine makers have committed to at least evaluating whether they might be able to respond. GlaxoSmithKline ($GSK), Pfizer ($PFE), Merck ($MRK), Johnson & Johnson ($JNJ) and Takeda all followed Sanofi's announcement by saying that they'd look into their existing vaccines and technologies for the potential to create a Zika vaccine. Sanofi and GSK have expertise with vaccines for mosquito-borne diseases. GSK has an approved jab for malaria and Sanofi is rolling out its vaccine for dengue fever. Story

> Perrigo ($PRGO), already recalling grape-flavored versions of its store brand for the popular cold med Mucinex for children, added three lots of the cherry-flavored version to its national recall. Report

> Drug distributor AmerisourceBergen ($ABC) cited its acquisition of compounder PharMEDium as providing some lift to its Q4 2015 earnings during a challenging period. Report

> Porton Biopharma has opened a new manufacturing facility in Porton Down in Wiltshire, U.K., allowing it to increase production of Erwinase, a treatment for a rare form of leukemia in children. Release

> Two weeks after it was approved by the European Commission, Norway became the first overseas country to approve the Enbrel biosimilar Benepali made by Samsung Bioepis. Report